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Abstract
Background: Autoimmune diseases with elevated circulating autoantibodies drive tissue damage and the onset of
disease. The Fcg receptors bind IgG subtypes modulating the clearance of circulating immune complexes (CIC). The
inner ear damage in Ménière’s disease (MD) could be mediated by an immune response driven by CIC. We
examined single-nucleotide polymorphism (SNPs) in the CD16A and CD32 genes in patients with MD which may
determine a Fcg receptor with lower binding to CIC.
Methods: The functional CD16A (FcgRIIIa*559A > C, rs396991) and CD32A (FcgRIIa*519A > G, rs1801274) SNPs were
analyzed using PCR-based TaqMan Genotyping Assay in two cohorts of 156 mediterranean and 112 Galicia patients
in a case-control study. Data were analyzed by c
2 with Fisher’s exact test and Cochran-Armitage trend test (CATT).
CIC were measured by ELISA for C1q-binding CIC.
Results: Elevated CIC were found in 7% of patients with MD during the intercrisis period. No differences were
found in the allelic frequency for rs396991 or rs1801274 in controls subjects when they were compared with
patients with MD from the same geographic area. However, the frequency of AA and AC genotypes of CD16A
(rs396991) differed among mediterranean and Galicia controls (Fisher’s test, corrected p = 6.9 × 10
-4 for AA;
corrected p = 0.02 for AC). Although genotype AC of the CD16A receptor was significantly more frequent in
mediterranean controls than in patients, [Fisher’s test corrected p = 0.02; OR = 0.63 (0.44-0.91)], a genetic additive
effect for the allele C was not observed (CATT, p = 0.23). Moreover, no differences were found in genotype
frequencies for rs396991 between patients with MD and controls from Galicia (CATT, p = 0.14). The allelic
frequency of CD32 (rs1801274) was not different between patients and controls either in mediterranean (p = 0.51)
or Galicia population (p = 0.11).
Conclusions: Elevated CIC are not found in most of patients with MD. Functional polymorphisms of CD16A and
CD32 genes are not associated with onset of MD.
Background
Ménière’s disease (MD) is a chronic disease defined by
recurrent spells of vertigo associated with sensorineural
hearing loss and tinnitus or aural fullness. Different
autoimmune diseases share susceptibility loci, but con-
sistent associations with multiple autoimmune disorders
have been restricted to three genes: the human leuko-
cyte antigen (HLA) DRB1 gene, the PTPN22 gene
encoding lymphoid tyrosine phosphatase LYP and the
gene encoding cytotoxic T lymphocyte-associated 4
(CTLA-4) receptor [1]. Autoimmune mechanisms
appear to be associated with the pathogenesis of some
types of sensorineural hearing loss (SNHL), [2,3] includ-
ing rapidly progressive bilateral SNHL (autoimmune
inner ear disease),[4] sudden SNHL [5] and MD [6-8].
Allelic variants of the HLA class II gene DRB1 and the
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gene have been associated to bilateral MD in mediterra-
nean population, suggesting an autoimmune process [9].
Diversity of populations may explain differences in
HLA-DRB1 associations found in British [10], German
[11], Japanese [12], Korean [13] or Spanish patients with
MD [14]. Moreover, the response to steroids therapy
and the finding of elevated levels of circulating immune
complexes (CIC) in some patients with MD, especially
in the active phase, has supported the hypothesis of
autoimmunity in MD [15,16]. A decrease in CIC clear-
ance could determine an increase of CIC levels which
are deposited in the blood vessels of the endolymphatic
sac, resulting in inflammation with increase in vascular
permeability and the development of endolymphatic
hydrops [16].
The Fcg receptors CD16A and CD32A connect the
innate and the adaptative immune response by transmit-
ting activating signals to natural killer lymphocytes and
myeloid cell upon recognition of Fc of IgG [17].
CD32A (FcgRIIa) exhibits low affinity for monomeric
IgG, but binds IgG CIC efficiently. Two genes and two
transcripts of FcgRIII have been described (FcgRIIIa, and
IIIb), which also bind IgG CIC and FcgRIIIa (CD16A)
has intermediate affinity for monomeric IgG and it is
involved in the removal of CIC [18]. CD32A is
expressed in all myeloid cells, platelets, and endothelial
cells, whereas CD16A is present on monocytes, macro-
phages, NK cells and g/δ T cells [17].
Fcg receptors subclasses display functionally relevant
genetically determined polymorphisms. So, FcgRIIa dis-
plays a G to A single nucleotide polymorphism (SNP) at
nucleotide 519 in the region specifying its ligand binding
domain, causing an arginine (R) to histidine (H) amino
acid substitution at position 131 (rs1801274). The
FcgRIIa-H131 allotype shows higher binding efficiency
for human IgG2 and IgG3 isoforms, compared to
FcgRIIa-R131. The FcgRIIIa gene displays a C to A sub-
stitution in exon 4 at nucleotide 559, resulting in a
valine (V) to phenylalanine (F) substitution at amino
acid position 158 (rs396991) [19]. IgG-induced NK cell
activity is increased among FcgRIIIa-V/V158 donors,
compared to FcgRIIIa-F/F158 individuals, due to a
higher affinity of the former allotype for IgG1, IgG3 and
IgG4 [18,20]. These low binding phenotypes has been
associated with susceptibility to recurrent viral infec-
tions, rheumatoid arthritis [21,22] and systemic lupus
erythematosus [23] and are clinically relevant because
they modify the clinical course and the response to ther-
apy of several human diseases [24].
The aim of this study was to analyze the FcgRIIa*519A
>Ga n dF c gRIIIa*559A > C SNPs in the Fc receptor
cluster in patients with definite MD.
Methods
Subjects
DNA Samples from 268 unrelated patients with MD and
770 controls from two ethnically defined regions were
included in a prospective multicenter study between
January 2004 and December 2009. All patients were
diagnosed according to the diagnostic scale for MD of
the American Academy of Otolaryngology- Head and
Neck Surgery (AAO-HNS) [25]. Group 1 consisted of
156 Caucasian patients from the east and southeast
areas of Spain (85 unilateral, 71 bilateral MD) that were
compared with 626 controls from the same area. Group
2 was recruited to replicate the results of group 1 and
included 112 (47 unilateral, 65 bilateral MD) Caucasian
patients and 144 controls from Galicia (northwest of
Spain). Five centers recruited samples from patients
with MD for this study: Hospital La Fe from Valencia,
Hospital Virgen de las Nieves from Granada, Hospital
de Poniente from El Ejido, Almeria (group 1) and Hos-
pital Santiago de Compostela and Hospital de Ponteve-
dra (group 2). Controls for group 1 were unrelated
Caucasian volunteer blood donors at Almeria and
Granada; controls for group 2 were provided by the
Spanish DNA BioBank http://www.bancoadn.org. The
selection of controls was matched by age and gender in
both populations. Caucasian subjects with a different
origin (Maghreb, Romani minority) were excluded to
avoid a substructure bias in the controls (Table 1).
The subject’s informed consent was obtained to parti-
cipate in the study according to the Declaration of
Helsinki and the local Institutional Board approved the
study. The clinical features and HLA-DRB1 and DQB1
genotyping of some patients with MD from both groups
were previously reported [14].
DNA extraction and genotyping
All genomic procedures were carried out at Department
of Immunology, Hospital Virgen de las Nieves, Granada,
Spain. Total genomic DNA was automatically isolated
from peripheral blood of patients and healthy controls
Table 1 Baseline characteristics of case and control
subjects
Variable Southeast population Northwest population
MD Control MD Control
Subjects 156 626 112 144
Female gender (%) 53.8 59.7 50.0 51.4
Age (years)
Mean 56.1 38.0 55.5 37.2
Median 56 37 58 38,5
Range 15-88 19-68 12-79 18-64
SD 13.1 9.5 13.8 13.1
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DNA Blood Mini M48 (192) kit from Qiagen. The geno-
typing of the FcgRIIa*519A > G (rs1801274) and
FcgRIIIa*559A > C (rs396991) SNPs were performed
using a predeveloped TaqMan SNP Genotyping Assays
(Applied Biosystems, Foster City, CA). The PCR reac-
tion was carried out using the Assays-on-Demand SNP
genotyping kit (AB). SNPs amplification assays were
used according to the manufacturer’si n s t r u c t i o n s .I n
short, 5 μl of reaction solution containing 10ng of DNA
was mixed with 2.5 μlo f2 ×T a q M a nU n i v e r s a lP C R
Mix (AB), 0.05 μl of predeveloped assay reagent from
the SNP genotyping product (AB) containing two pri-
mers and two MGB-Taqman probes and 1,45 μlo f
desionizated water. Reaction conditions consisted of pre-
incubation at 50°C for 2 minutes and at 95°C for 10
minutes, followed by 40 cycles at 95°C for 15 seconds
and at 60°C for 1 minute. Amplifications and analysis
were performed in an ABI Prism 7500 Sequence Detec-
tion System (AB) using the SDS 1.4 software for allelic
discrimination (AB).
Determination of circulating immunocomplexes
Serum samples from 331 patients (85 mediterranean and
203 Galicia patients) were obtained to determine CIC
concentrations. So, an Autostat™II test for C1q CIC kit
(HYCOR, Agilent Technologies, Amstelveen, The Neth-
erlands) was used to detect immune complexes contain-
ing both C1q and IgG in a Hytec 288 Plus System
(HYCOR). Positive and negative controls and reference
values were provided by the manufacturer (0-40 μg/ml).
Statistical analysis
Allelic and genotype frequencies were calculated by
direct counting. Hardy-Weinberg equilibrium was tested
for each SNP among controls. For 2 × 2 contingency
tables of allele frequencies of patients with MD and con-
trols, odds ratios (ORs) and 95% confidence intervals
(95% CI), c
2 test and Fisher’s exact test were calculated
to determine the exact two-sided p-values using SPSS
Software (SPSS Inc., Chicago, IL, USA). Genotype fre-
quencies were compared for each of the 2 × 3 contin-
g e n c yt a b l e sb yC o c h r a n - A r m i t a g et r e n dt e s t ,w h i c h
may have more power than Fisher’s exact test if a trend
exists across genotype categories under the additive
genetic effect model. Probability values (p)w e r ec o r -
rected by multiplying the p value by the number of gen-
otypes compared. p-values lower than 0.05 were
considered statistically significant.
Results
The CD32 (FcgRIIa*519A > G) and CD16A
(FcgRIIIa*559A > C) SNPs in the Fcg receptors were
selected to investigate their association with MD.
Genotype distributions of both SNPs in mediterranean
and Galicia controls exhibited Hardy- Weinberg equili-
brium (data not shown), and the minor allele frequen-
cies of all SNPs were over 5% in controls from both
groups.
First, the frequencies of genotypes AA and AC for
FcgRIIIa*559A > C were significantly different in con-
trols from southeast and northwest of Spain (Table 2).
So, the genotype AA of FcgRIIIa (low binding pheno-
type) is more common in Galicia than in mediterranean
population (Fisher’se x a c tt e s t ,p=6 . 9×1 0
-4). Second,
we compared the genotypes distribution of both SNPs
between patients with uni and bilateral MD (Table 3).
There was no difference in the genotype of both
FcgRIIa*519A > G and FcgRIIIa*559A > C SNPs
between patients with one or both ears affected either in
mediterranean or Galicia population (all, p > 0.05).
The CD32 allelic frequencies (rs1801274) did not dif-
fer between patients and controls either in southeast
(p = 0.51) or northwest groups (p = 0.11). Moreover,
AA and AG genotypes did not increase the risk for MD
in any of both populations (Table 4).
In addition, no differences were found in the allelic
frequency of CD16A (rs396991) in controls subjects
when they were compared with patients with MD from
the same geographic area. Although the genotype AC of
CD16A receptor was significantly more frequent in
mediterranean controls than in MD patients (OR = 0.63
(0.44-0.91), Fisher’s test, corrected p = 0.02), a genetic
additive effect for the allele C was not observed (Coch-
cran-Armitage trend test, p = 0.23). The genotype AA
of FcgRIIIa (rs396991) encoding the FcgRIIIa-F/F158
phenotype was not associated with MD (95% CI, 1.04-
2.10; corrected p = 0.06) (Table 5). Moreover, we repli-
cated our observations in the northwest group, and no
differences were found in genotype frequencies for
rs396991 between patients with MD and controls from
Galicia (CATT, p = 0.11).
Circulating immunocomplexes were investigated in
331 patients with MD. There was an increase of CIC in
25 patients (7.6%). No difference was found in the fre-
quency of elevated CIC between patients with unilateral
(7%) or bilateral involvement (8.4%). In addition, we did
not found association between elevated CIC and the
homozygous genotype AA of FcgRIIIa either in mediter-
ranean (p = 0.42) or Galicia (p = 0.64) patients in our
series.
Discussion
Our shows that heterogeneity within caucasian popula-
tion should be consider in genetic association studies.
The distribution of frequencies of CD16A genotypes AA
and AC was different in Galicia and mediterranean con-
trols. The genotype frequencies in our Mediterranean
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vious study from the same geographical area [21]. The
difference of CD16A with the Galicia population may
indicate a differential immunogenetic background
between populations.
These two SNPs were chosen because they determine
a low binding phenotype for Fcg receptors and their
consistent association with rheumatoid arthritis [21,22]
and systemic lupus erythematosus [23].
The genotype AC of the FcgRIIIa*559A > C (CD16A)
gene is overrepresented in mediterranean controls and it
may confer some protection for MD in mediterranean
patients, although the trend test did not confirm an
additive effect in homozygous subjects. In addition, the
genotype AA of CD16A was marginally associated with
MD in mediterranean population. However, these find-
ing could not be replicated in the population from
Galicia within the same country. The allele A encodes
for a V to F substitution at amino acid position 158,
resulting in an FcgRIIIa allotype with a lower affinity.
The lower affinity of this Fc receptor for IgG subclasses
may decrease the binding efficiency for IgG1, IgG3 and
IgG4 complexes, resulting in a lower clearance of CIC.
We cannot support the hypothesis that FcgRp o l y -
morphisms determine a CIC-mediated damage in the
inner ear of patients with MD, although the efficiency of
FcgR-IgG interaction may predict the efficacy of CIC
clearance [17]. A less efficient CIC clearance may lower
the threshold for complexes deposition in the vascular
endothelium, with the induction of inflammation
Table 2 Distribution of rs396991 (CD16A) and rs1801274 (CD32) genotypes and phenotypes in controls subjects from
southeast and northwest populations
Genotype Phenotype Southeast Northwest Fisher exact p values Corrected p
CD16A N = 626 (%) N = 141 (%)
AA 176F/F 221 (35.3) 73 (51.8) 2.3 × 10
-4 6.9 × 10
-4
AC 176F/V 314 (50.2) 54 (38.3) 7 × 10
-3 0.02
CC 176V/V 91 (14.5) 14 (9.9) 0.09 NS
CD32 N = 349 (%) N = 144 (%)
AA 131R/R 95 (27.2) 28 (19.4) 0.04 NS
AG 131R/H 162 (46.4) 83 (57.6) 0.01 0.03
GG 131H/H 92 (26.4) 33 (22.9) 0.25 NS
Low affinity binding phenotypes are 176F/F and 131 R/R.
Table 3 Distribution of CD16a and CD32 genotypes in
patients with uni and bilateral MD (c2 test)
Southeast group Unilateral Bilateral P value
CD16A genotype N = 85 (%) N = 71 (%)
AA 37 (43.5) 33 (46.5) 0.91
AC 33 (38.8) 27 (38.0)
CC 15 (17.6) 11 (15.5)
CD32 genotype N = 85(%) N = 71(%)
AA 21 (24.7) 22 (31.0) 0.59
AG 42 (49.4) 29 (40.8)
GG 22 (25.9) 20 (28.2)
Northwest group Unilateral Bilateral P value
CD16A genotype N = 45 (%) N = 65 (%)
AA 17 (37.8) 29 (44.6) 0.34
AC 22 (48.9) 28 (43.1)
CC 6 (13.3) 8 (12.7)
CD32 genotype N = 47 (%) N = 65 (%)
AA 12 (25.5) 18 (27.7) 0.84
AG 25 (53.2) 36 (55.4)
GG 10 (21.3) 11 (16.9)
Table 4 Frequency of CD32 alleles and genotypes among
MD patients and healthy controls (Fisher’s exact test)
Southeast MD N =
155 (%)
Controls
N = 349 (%)
OR (95% CI) P value
AA 43 (27.7) 95 (27.2) 1,03 (0.67-1.57) 0.49
AG 70 (45.2) 162 (46.4) 0,95 (0.65-1.39) 0.43
GG 42 (27.1) 92 (26.4) 1,04 (0.68-1.59) 0.47
Allele 2n = 310 (%) 2n = 698 (%) 1,00 (0.77-1.31) 0.51
A 156 (50.3) 352 (50.4)
G 154 (49.7) 346 (49.6)
Northwest MD N =
112 (%)
Controls
N = 144 (%)
OR (95% CI) P value
AA 30 (26.8) 28 (19.4) 1,52 (0.84-2.72) 0,11
AG 61 (54.5) 83 (57.6) 0.88 (0.53-1.45) 0.35
GG 21 (18.8) 33 (22.9) 0.77 (0.42-1.43) 0.26
Allele 2n = 224 (%) 2n = 228 (%) 1.25 (0.88-1.79) 0.11
A 121 (54.0) 139 (48.3)
G 103 (46.0) 149 (51.7)
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arthritis [20].
The rs 396991 of CD16A has been associated with
rheumatoid arthritis [21,22], systemic lupus erythemato-
sus [23,24], vasculitis [26], demyelinating disease [27],
immune thrombocytopenic purpura [28] and myasthenia
gravis [29]. This is the first report describing an associa-
tion between MD and polymorphisms of CD16A recep-
tor in mediterranean population, although we could not
replicate this effect in the Galicia population. We also
previously found that the HLA class II allele DRB1*1101
was associated in mediterranean patients with MD, but
not association was found in patients from Galicia [14].
MD is multifactorial and the interaction of several
genes with the environment is probably involved. Sev-
eral mutations have been described in the coagulation
factor C homology (COCH) gene (14q12-13), which
cause the autosomal dominant SNHL DFNA9
(OMIM603196) [30], and a high prevalence of symp-
toms of MD has been described in European families
with a P51S mutation in exon 4 of COCH gene [31].
However, these mutations were not found in patients
with MD [32].
Many tests have been developed for the detection of
CIC, including polyethylene glycol (PEG) precipitation
and radial immunodiffusion and cellular based assays.
No single procedure appears to detect all types of CIC,
however, those procedures which detect CIC containing
fragments of complement (e.g. C1q and C3d) appear to
detect clinically relevant events. Although several reports
have found elevated CIC in 54-96% of patients with MD
using the PEG precipitation assay [15,16], another study
using our method, a solid phase immunosorbent assay
(ELISA) for C1q and IgG also found an elevation of
CICs in 4% of 49 patients with MD [34]. Our results
confirm this study and found elevated CIC in 7.4% of
331 patients. Moreover, subanalysis of patients with
bilateral MD did not show a higher frequency of ele-
v a t e dC I C .O u rd a t ac a n n o ts u p p o r tt h a tp a t h o p h y s i o l -
ogy of MD is different in patients with uni or bilateral
involvement.
Histopathology studies in temporal bones from
patients with MD have shown endolymphatic hydrops
and vestibular fibrosis in the inner ear. Immunohisto-
chemistry have found deposits of C3 and C1q in the
membranous labyrinth located at the basal membrane,
subepithelial connective tissue, vestibular ganglion and
endolymphatic sac of patients with MD [35,36]. It
appears that immune injury may be induced in the
inner ear at sites where CIC are deposited in the vessels.
It is hypothesized that deposits of CIC in the vessels of
the stria vascularis may interfere with the recycling of
K
+ ions, resulting in an osmotic imbalance, cellular
stress and probably dysfunction of fibrocytes of the
spiral ligament. The flux of K
+ ions into the endolym-
phatic compartment from the stria vascularis reflects the
current flow underlying the endolymphatic potential
[37]. In a guinea pig model, it appears that type I fibro-
cytes and other cells are damaged before the onset of
hydrops, but the mechanism is unknown [38].
One of the limitations of this study is that we could
not demonstrate an association between patients with
the genotype AA of CD16A and elevated CIC. This
could be explained because blood samples were not
obtained in an acute phase of the disease, and CIC levels
may fluctuate within the same patient according to the
Table 5 Frequency of CD16A alleles and genotypes among MD patients and healthy controls
Southeast MD N = 156 (%) Controls N = 626 (%) OR (95% CI) Fisher’s exact p values Corrected p
AA 70 (44.9) 221 (35.3) 1.49 (1.05-2.12) 0.018 0.054
AC 60 (38.5) 314 (50.2) 0.62 (0.43-0.89) 0.006 0.018
CC 26 (16.7) 91 (14.5) 1.17 (0.73-1.89) 0.29 NS
Allele 2n = 312 (%) 2n = 1252 (%) 1.17 (0.91-1.52) 0.13 NS
A 200 (64.1) 756 (60.4)
C 112 (35.9) 496 (39.6)
Northwest MD N = 110 (%) Controls N = 141 (%) OR (95% CI) Fisher’s exact p values Corrected p
AA 46 (41.8) 73 (51.8) 0.67 (0.40-1.11) 0.07 NS
AC 50 (45.5) 54 (38.3) 1.34 (0.80-2.23) 0.15 NS
CC 14 (12.7) 14 (9.9) 1.32 (0.60-2.91) 0.31 NS
Allele 2n = 220 (%) 2n = 282 (%) 0.75 (0.51-1.09) 0.08 NS
A 142 (64.5) 200 (70.9)
C 78 (35.5) 82 (29.1)
No additive effect was observed in homozygous subjects with Cochran-Armitage trend test in the southeast (p = 0.23) and the northwest group (p = 0.14).
Lopez-Escamez et al. BMC Medical Genetics 2011, 12:2
http://www.biomedcentral.com/1471-2350/12/2
Page 5 of 7disease activity. Our next study will look at the CIC
level during the acute phases of MD to compare them
with basal CIC levels in subjects with genotype AA of
CD16A.
Conclusions
Elevated CIC were found in 7% of patients with MD.
Polymorphisms of CD16A (FcgRIIIa*559A > C, rs396991)
and CD32A (FcgRIIa*519A > G, rs1801274) genes are not
associated with onset of MD.
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